You’re using a public version of DrugPatentWatch with 5 free searches available | Register to unlock more free searches. CREATE FREE ACCOUNT

Last Updated: April 24, 2024

Claims for Patent: 7,247,314

✉ Email this page to a colleague

« Back to Dashboard

Summary for Patent: 7,247,314

Title:	Biocompatible material composition adaptable to diverse therapeutic indications
Abstract:	A biocompatible material genus serves as the foundation for multiple material composition species, each adapted to a specific therapeutic indication.
Inventor(s):	Hnojewyj; Olexander (Saratoga, CA), Milo; Charles F. (Atherton, CA), Cruise; Gregory M (Fremont, CA)
Assignee:	Neomend, Inc (Irvine, CA)
Application Number:	11/002,837
Patent Claims:	1. A method comprising providing a protein solution, providing a polymer solution including a derivative of a hydrophilic polymer with a functionality of at least three, mixing the protein solution and the polymer solution, the protein solution and the polymer solution cross-linking to form a non-liquid hydrogel composition having a degradation time in situ that is from 1 week to 6 months, selecting a therapeutic agent comprising cells, and causing the therapeutic agent to become incorporated into the hydrogel composition, the degradation time being within a desired time frame for the cells to remodel tissue. 2. A method comprising providing a protein solution, providing a polymer solution including a derivative of a hydrophilic polymer with a functionality of at least three, the polymer solution comprising 17% w/w 4-arm poly(ethylene glycol) tetra-succinimidyl glutarate, MW 10,000, in water, mixing the protein solution and the polymer solution, the protein solution and the polymer solution cross-linking to form a non-liquid hydrogel composition, selecting a therapeutic agent, and causing the therapeutic agent to become incorporated into the hydrogel composition. 3. A method comprising providing a protein solution comprising 25% w/w albumin supplemented with 75 mM sodium carbonate and 75 mM sodium bicarbonate, providing a polymer solution including a derivative of a hydrophilic polymer with a functionality of at least three, mixing the protein solution and the polymer solution, the protein solution and the polymer solution cross-linking to form a non-liquid hydrogel composition, selecting a therapeutic agent, and causing the therapeutic agent to become incorporated into the hydrogel composition. 4. A method as in claim 2 or 3 wherein the therapeutic agent is a pharmaceutical. 5. A method as in claim 4 wherein the hydrogel composition has a degradation time in situ that is within a desired time frame for release of the selected pharmaceutical. 6. A method as in claim 5 wherein the desired time frame is from 1 week to 1 year. 7. A method as in claim 1 wherein the polymer solution comprises 17% w/w 4-arm poly(ethylene glycol) tetra-succinimidyl glutarate, MW 10,000, in water. 8. A method as in claim 1 wherein the protein solution comprises 25% w/w albumin supplemented with 75 mM sodium carbonate and 75 mM sodium bicarbonate. 9. A method as in claim 8 wherein the albumin is human serum albumin. 10. A method as in claim 1 or 2 or 3 wherein the protein is a natural protein. 11. A method as in claim 1 or 2 or 3 wherein the protein is a recombinant protein. 12. A method as in claim 2 or 3 wherein the therapeutic agent is cells. 13. A method as in claim 12 wherein the hydrogel composition has a degradation time in situ that is within a desired time frame for the cells to remodel tissue. 14. A method as in claim 13 wherein the desired time frame is from 1 week to 6 months. 15. A method as in claim 1 or 2 or 3 wherein the hydrogel composition has a gelation time in situ of 5 30 seconds. 16. A method as in claim 1 or 2 or 3 wherein the hydrogel composition comprises a three-dimensional network. 17. A method as in claim 16 wherein the network degrades over time back to a liquid form. 18. A method as in claim 3 wherein the albumin is human serum albumin.

Details for Patent 7,247,314

Subscribe to access the full database, or Try a Trial
Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Grifols Therapeutics Llc	ALBUKED, PLASBUMIN-20, PLASBUMIN-25, PLASBUMIN-5	albumin (human)	For Injection	101138	10/21/1942	⤷ Try a Trial	2018-11-06
Baxalta Us Inc.	BUMINATE, FLEXBUMIN	albumin (human)	Injection	101452	03/03/1954	⤷ Try a Trial	2018-11-06
Csl Behring Ag	ALBURX	albumin (human)	Injection	102366	07/23/1976	⤷ Try a Trial	2018-11-06
Grifols Biologicals Llc	ALBUTEIN	albumin (human)	Injection	102478	08/15/1978	⤷ Try a Trial	2018-11-06
Instituto Grifols, S.a.	HUMAN ALBUMIN GRIFOLS	albumin (human)	Injection	103352	02/17/1995	⤷ Try a Trial	2018-11-06
Instituto Grifols, S.a.	HUMAN ALBUMIN GRIFOLS	albumin (human)	Injection	103352	06/11/2003	⤷ Try a Trial	2018-11-06
>Applicant	>Tradename	>Biologic Ingredient	>Dosage Form	>BLA	>Approval Date	>Patent No.	>Expiredate

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.